Alharbi Mariam S
Internal Medicine Department, College of Medicine, Qassim University, Buraydah, Saudi Arabia.
EFORT Open Rev. 2022 Mar 17;7(3):240-246. doi: 10.1530/EOR-21-0116.
The aim of the study was to conduct a literature review on growth hormone therapy in short-stature patients with kyphoscoliosis. The search strategy was performed in which all the relevant papers published in 20 years were included on Pub Med, Central, and Google scholar by using keywords short stature, growth hormones, adverse events of growth hormones in kyphoscoliosis, safety. The study investigation supports the idea that giving human growth hormone (HGH) to a diverse population of short-statured children does not enhance the occurrence of scoliosis. Patients on HGH therapy for progressing scoliosis had syndromes in which scoliosis was more prevalent in an age-matched group. Short stature attributed to progressive growth failure is prevalent in all mucopolysaccharidosis (MPS) disorders, as per the existing research on growth and growth hormone in MPS. MPS should be explored in children who are being tested for short stature since growth failure might be the presenting symptom.
本研究的目的是对脊柱后凸侧弯的身材矮小患者进行生长激素治疗的文献综述。采用的检索策略是，通过使用关键词“身材矮小”“生长激素”“脊柱后凸侧弯中生长激素的不良事件”“安全性”，在PubMed、Central和谷歌学术上纳入20年内发表的所有相关论文。该研究调查支持这样一种观点，即给予不同人群的身材矮小儿童生长激素（HGH）不会增加脊柱侧弯的发生率。接受HGH治疗以改善脊柱侧弯的患者存在一些综合征，在年龄匹配组中脊柱侧弯更为普遍。根据现有关于黏多糖贮积症（MPS）生长和生长激素的研究，因进行性生长衰竭导致的身材矮小在所有MPS疾病中都很常见。对于身材矮小正在接受检查的儿童，应探索是否存在MPS，因为生长衰竭可能是首发症状。
